All In Biotech

Drug Trial Radar · NCT00478192

Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

A Phase IIIb, Randomized, Double-Blind, Parallel Group, Multi-Center, Study to Assess the Efficacy and Safety of Multiple 30 Minute Infusions of YM087 (Conivaptan) in Subjects With Euvolemic or Hypervolemic Hyponatremia

Last checked: Nov 19, 2026Latest source record: May 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

50

Actual

Start

Apr 2007

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 24, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to assess the efficacy and safety of multiple infusions of conivaptan in subjects with euvolemic or hypervolemic hyponatremia

Conditions

  • Hyponatremia

Interventions

  • ConivaptanDrug

    premix bag

  • PlaceboDrug

    premix bag

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation.Time frame: Baseline and 48 hours

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Tucson, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Denver, Colorado

  • Site not named

    Jacksonville, Florida

  • Site not named

    Port Charlotte, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Hazard, Kentucky

  • Site not named

    Detroit, Michigan

  • Site not named

    Omaha, Nebraska

  • Site not named

    The Bronx, New York

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Fairfield, Ohio

  • Site not named

    Toledo, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Orangeburg, South Carolina

  • Site not named

    Coimbatore, India

  • Site not named

    Indore, India

  • Site not named

    Jaipur, India

  • Site not named

    Karnāl, India

  • Site not named

    Visakhapatnam, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.